—
C+
C+ The full Closelook — membership. Open the C+ overview

Hims Hers Health Inc (HIMS) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Hims Hers Health Inc

HIMS in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Hims & Hers Health runs a direct-to-consumer platform that links patients online with licensed clinicians for prescription and over-the-counter care. It sells personalised treatments and products across skincare, hair care, sexual health, weight loss, hormone health and mental health, alongside lab testing that checks a range of body markers. Consultations, follow-up support and test results are delivered through its website and app, with some products also reaching customers through retail partners and physical stores. The company operates across the United States and several other countries, including the United Kingdom, Canada, Germany, Ireland, France, Spain and Australia, and is based in San Francisco.
Where it sits in the stack
Hims & Hers does not carry a Closelook index seat and sits outside the AI build-out stack that our indices track. It belongs instead to the broader healthcare and consumer-health corner of our coverage universe, working as a direct-to-consumer telehealth and specialty drug distributor rather than a supplier to any compute, chip or data-centre layer.
Who it is priced against
The diary has no Closelook peer group recorded for Hims & Hers. The comparison the market draws most often is with Teladoc Health, another consumer-facing telehealth business built around remote clinician access.
Why Closelook tracks it
Hims & Hers holds no seat in our indices and carries no Closelook score across any module. It has not appeared in an edition or a quote so far, so its house-level coverage has not yet begun.
What the diary watches
The diary watches whether direct-to-consumer prescribing keeps expanding into new chronic-condition categories and further countries, which would widen the base for its subscription model.

Hims Hers Health Inc (HIMS) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for HIMS, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 2 analyst actions on the wire · latest: price target by Truist, 2026-08-24

The Street on this name

Analyst actions and the latest print for HIMS from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Truist — target 32 from 27 Target raised to $32 from $27 (+2.4% to spot) 2026-08-24
  • Price target Barclays — target 35 Target set to $35 (+6.6% to spot) 2026-08-20

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against HIMS on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 90 m USD in FY2025

Dividends and capital return

What HIMS pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 90 m USD 1.4% of today's market value
  • Share count +9.0% in FY2025 135 m USD of stock-based compensation in the year
  • Capital returned 90 m USD · 122% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Hims Hers Health Inc (HIMS)?

Hims Hers Health Inc trades as HIMS on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is HIMS in a Closelook index?

Not currently — Hims Hers Health Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does HIMS trade against its moving averages?

Mixed moving-average stack: Trades -8.1% vs the 50-day and -0.5% vs the 200-day average, 57.3% below the 52-week high and +103% off the 52-week low; a golden cross printed 35 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Hims Hers Health Inc do?

Hims & Hers Health runs a direct-to-consumer platform that links patients online with licensed clinicians for prescription and over-the-counter care. It sells personalised treatments and products across skincare, hair care, sexual health, weight loss, hormone health and mental health, alongside lab testing that checks a range of body markers. Consultations, follow-up support and test results are delivered through its website and app, with some products also reaching customers through retail partners and physical stores. The diary has no Closelook peer group recorded for Hims & Hers. The comparison the market draws most often is with Teladoc Health, another consumer-facing telehealth business built around remote clinician access.

Where does Hims Hers Health Inc sit in the AI build-out?

Hims & Hers does not carry a Closelook index seat and sits outside the AI build-out stack that our indices track. It belongs instead to the broader healthcare and consumer-health corner of our coverage universe, working as a direct-to-consumer telehealth and specialty drug distributor rather than a supplier to any compute, chip or data-centre layer. Hims & Hers holds no seat in our indices and carries no Closelook score across any module. It has not appeared in an edition or a quote so far, so its house-level coverage has not yet begun.

Does Hims Hers Health Inc pay a dividend?

No cash distribution shows in Hims Hers Health Inc’s price series over the last three years. In fiscal 2025 the company bought back 90 m USD of its own shares, 122% of that year’s free cash flow. The share count rose 9.0% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Hims Hers Health Inc recently?

The most recent analyst action on Hims Hers Health Inc on the Closelook wire is a price target by Truist on 2026-08-24 (target 32 from 27). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for HIMS, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.